Concourse Financial Group Securities, Inc. Biotechnology

Concourse Financial Group Securities, Inc.

$1.64 Billion
Q3 2024

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade	Trade History
NVO Novo Nordisk A S	$195B	$5.55 Million 0.34% of portfolio	46,584	Q3 2024 Reduced 1.06%
VRTX Vertex Pharmaceuticals Inc	$105B	$2.27 Million 0.14% of portfolio	4,891	Q3 2024 Reduced 0.45%
SAVA Cassava Sciences Inc	$113M	$289,000 0.02% of portfolio	9,827	Q3 2024 Added 67.52%
INCY Incyte Corp	$15.7B	$99,000 0.01% of portfolio	1,503	Q3 2024 Reduced 11.33%
EXEL Exelixis, Inc.	$11.6B	$87,000 0.01% of portfolio	3,361	Q3 2024 Reduced 1.12%
XENE Xenon Pharmaceuticals Inc.	$2.39B	$78,000 0.0% of portfolio	2,000	Q4 2019 Added 100.0%
NTLA Intellia Therapeutics, Inc.	$775M	$62,000 0.0% of portfolio	3,047	Q3 2024 Added 20.63%
REGN Regeneron Pharmaceuticals, Inc.	$74.7B	$57,000 0.0% of portfolio	55	Q3 2024 Added 19.57%
HALO Halozyme Therapeutics, Inc.	$7.35B	$57,000 0.0% of portfolio	998	Q3 2024 Added 7,576.92%
VKTX Viking Therapeutics, Inc.	$3.01B	$44,000 0.0% of portfolio	700	Q3 2024 Added 16.67%
MRNA Moderna, Inc.	$16.5B	$43,000 0.0% of portfolio	650	Q3 2024 Reduced 18.85%
JAZZ Jazz Pharmaceuticals PLC	$7.61B	$38,000 0.0% of portfolio	348	Q3 2024 Added 2,075.0%
SRPT Sarepta Therapeutics, Inc.	$10.9B	$29,000 0.0% of portfolio	233	Q3 2024 Reduced 3.32%
TECH Bio Techne Corp	$2.88B	$15,000 0.0% of portfolio	199	Q3 2024 Reduced 16.74%
CRSP Crispr Therapeutics Ag	$3.1B	$9,000 0.0% of portfolio	200	Q3 2024 Reduced 25.65%
GMAB Genmab A/S	$14.6B	$9,000 0.0% of portfolio	388	Q3 2024 Reduced 23.02%
SAGE Sage Therapeutics, Inc.	$330M	$7,000 0.0% of portfolio	1,000	Q1 2024 Reduced 0.1%
LGND Ligand Pharmaceuticals Inc	$1.79B	$7,000 0.0% of portfolio	72	Q2 2023 Reduced 17.24%
AMRN Amarin Corp Plcuk	$222M	$5,000 0.0% of portfolio	8,000	Q4 2022 New
HUMA Humacyte, Inc.	$475M	$5,000 0.0% of portfolio	1,000	Q2 2024 New
HRTX Heron Therapeutics, Inc.	$184M	$2,000 0.0% of portfolio	1,280	Q3 2024 Reduced 18.99%
ORMP Oramed Pharmaceuticals Inc.	$92.8M	$2,000 0.0% of portfolio	1,000	Q3 2021 New
RPRX Royalty Pharma PLC	$12.9B	$2,000 0.0% of portfolio	89	Q3 2024 Reduced 72.7%
RVNC Revance Therapeutics, Inc.	$212M	$1,000 0.0% of portfolio	570	Q1 2024 New
BMRN Biomarin Pharmaceutical Inc	$12.5B	$1,000 0.0% of portfolio	15	Q3 2024 Reduced 70.59%
TSVT 2seventy Bio, Inc.	$94.3M	$0 0.0% of portfolio	0	Q3 2024 New
FDMT 4 D Molecular Therapeutics, Inc.	$179M	$0 0.0% of portfolio	0	Q3 2024 New
ETNB 89bio, Inc.	$320M	$0 0.0% of portfolio	0	Q3 2024 New
AADI Aadi Bioscience, Inc.	$75.7M	$0 0.0% of portfolio	0	Q3 2024 New
ABCL Ab Cellera Biologics Inc.	$833M	$0 0.0% of portfolio	0	Q3 2024 New
ABEO Abeona Therapeutics Inc.	$32.9M	$0 0.0% of portfolio	0	Q3 2024 New
ABSI Absci Corp	$266M	$0 0.0% of portfolio	0	Q3 2024 New
ACIU Ac Immune Sa	$227M	$0 0.0% of portfolio	0	Q3 2024 New
ACAD Acadia Pharmaceuticals Inc	$2.79B	$0 0.0% of portfolio	0	Q3 2024 New
ACHL Achilles Therapeutics PLC	$48.5M	$0 0.0% of portfolio	0	Q3 2024 New
ATNM Actinium Pharmaceuticals, Inc.	$32.2M	$0 0.0% of portfolio	0	Q3 2024 New
ABOS Acumen Pharmaceuticals, Inc.	$66.8M	$0 0.0% of portfolio	0	Q3 2024 New
ACXP Acurx Pharmaceuticals, Inc.	$9.36M	$0 0.0% of portfolio	0	Q3 2024 New
ADAG Adagene Inc.	$84.2M	$0 0.0% of portfolio	0	Q3 2024 New
ADGI Adagio Therapeutics, Inc.	$505M	$0 0.0% of portfolio	0	Q3 2024 New
ADAP Adaptimmune Therapeutics PLC	$101M	$0 0.0% of portfolio	0	Q3 2024 New
ADPT Adaptive Biotechnologies Corp	$929M	$0 0.0% of portfolio	0	Q3 2024 New
ADCT Adc Therapeutics Sa	$146M	$0 0.0% of portfolio	0	Q3 2024 New
ACET Adicet Bio, Inc.	$36.8M	$0 0.0% of portfolio	0	Q3 2024 New
ADMA Adma Biologics, Inc.	$3.64B	$0 0.0% of portfolio	0	Q3 2024 New
AVTE Aerovate Therapeutics, Inc.	$62.3M	$0 0.0% of portfolio	0	Q3 2024 New
AGIO Agios Pharmaceuticals, Inc.	$1.89B	$0 0.0% of portfolio	0	Q3 2024 New
AIKI A Ikido Pharma Inc.	$20.8M	$0 0.0% of portfolio	0	Q3 2024 New
AIM Aim Immuno Tech Inc.	$10.1M	$0 0.0% of portfolio	0	Q3 2024 New
AKBA Akebia Therapeutics, Inc.	$324M	$0 0.0% of portfolio	0	Q3 2024 New

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.